BioNTech | 14/03/2023 | By Sudeep Soparkar | 351
BioNTech to invest $43 M in German facility for mRNA vaccine
With the facility, BioNTech is seeking more control over the supply chain
BioNTech | 04/02/2023 | By Sudeep Soparkar | 358
BioNTech | 15/11/2022 | By Sudeep Soparkar | 530
BioNTech 2nd phase of Covid 19 trials completed
The vaccine, based on messenger RNA (mRNA) technology, is one of the most widely used worldwide against COVID, but has yet to receive an approval in China, which has relied only on domestically-developed vaccine
BioNTech | 12/05/2022 | By Sudeep Soparkar | 354
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy